MedTrace Logo

Blood-based Biomarkers for Alzheimer's Disease at the Primary Care Level.

NCT07666113 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 240

Last updated 2026-06-24

No results posted yet for this study

Summary

The goal of this study is to determine how blood biomarker tests (ptau217 and ptau217/Aβ42) performed in primary care influence the patient trajectory in individuals with cognitive concerns.

Participants will provide a blood sample for biomarker testing and undergo clinical assessments as part of diagnostic evaluation.

Conditions

  • Alzheimer's Disease (AD)

Interventions

DIAGNOSTIC_TEST

ptau217

Quantitative measurement of Tau phosphorylated at threonine 217 (pTau 217) in human K2EDTA plasma.

Sponsors & Collaborators

  • Universitaire Ziekenhuizen KU Leuven

    lead OTHER

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
55 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-05-26
Primary Completion
2030-04-30
Completion
2038-04-30

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07666113 on ClinicalTrials.gov